Nordic Nanovector and Heidelberg Pharma GmbH have entered a research agreement to develop novel treatment for leukaemia.

According to the agreement, the two partners will jointly develop novel antibody drug conjugates (ADCs) to treat leukaemia.

The agreement enables Nordic Nanovector to strengthen its product pipeline.

Myriad RBM and Sanofi have entered an agreement to analyse the cardiovascular risk in diabetic patients using biomarkers analysis.

"Myriad RBM and Sanofi have entered an agreement to analyse the cardiovascular risk in diabetic patients using biomarkers analysis."

Under the agreement, Sanofi will be responsible to provide 5,300 serum samples of patients from evaluation of Lixisenatide in acute coronary syndrome (ELIXA) trial. Myraid RBM will analyse the samples with CustomMAP platform to identify the biomarkers to predict cardiovascular and microvascular risk in diabetic patients.

Relief Therapeutics and FirstString Research have entered a partnership to further advance the clinical development of atexakin alfa in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, FristString will gain financial support from the US Government to submit an investigational new drug (IND) application of the drug to the FDA.

The agreement allows the partners to strengthen their research and commercial relationship.

Ritter Pharmaceuticals plans for an underwritten public offering of its common stock shares. Aegis Capital is acting as a sole book running manager to the company for the offering.

The company plans to use the funds to increase the working capital and for other general corporate purposes.

Everstone Capital Management has invested $33m to acquire a 70% stake in Rubicon Research.

The company has acquired the stakes from Kotak Private Equity and another undisclosed private investor.

Rubicon Research will use the funds to accelerate its growth.